Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Highlighting Exosomes' Function in Cardiovascular Diseases

Laksono S., Setianto B., Prawara AS., Dwiputra B.

Prospective Study on Cardiovascular Disease, published in Curr Cardiol Rev (2022) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Curr Cardiol Rev (2022)
Reported sample size
—
Source database
Europe PMC
PMID
33563169
PMCID
PMC9615217
DOI
10.2174/1573403x17666210204153526
Citations
2

Abstract (original English)

Exosomes, as one of the extracellular vesicles' subgroups, played an important role in the cell to cell communication. The cargos and surface protein of exosomes have been known to affect the cardiovascular system both positively and negatively in chronic heart failure, ischemic heart disease, and atherosclerosis. There have been several exosomes that emerged as potential diagnostic and prognostic markers in cardiovascular patients. However, the conditions affecting the patients and the method of isolation should be considered to create a standardized normal value of the exosomes and the components. CPC-derived exosomes, ADSCs-derived exosomes, and telocyte- derived exosomes have been proven to be capable of acting as a therapeutic agent in myocardial infarction models. Exosomes have the potential to become a diagnostic marker, prognostic marker, and therapeutic agent in cardiovascular diseases.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansCardiovascular DiseasesMyocardial InfarctionCell CommunicationExosomes

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research